Cho et al., 2018 |
South Korea |
RCT |
Primary: post-operative VNRS pain scores, total number of rescue analgesics used in 48 hours after the operation |
21-60 Mean (SD): Intervention –39.6(9.8) Control –41.7(11.3) |
60 (30/30) |
Intervention: ultrasound-guided RSB Control: no block |
Gynecologic laparoscopic surgery |
Yes |
I-II |
7.5 mL 0.25% ropi-vacaine bilaterally |
Fentanyl, ketorolac |
Cowlishaw et al., 2017 |
- |
RCT |
Analgesic and antiemetic consumption, pain scores (VAS), nausea, vomiting, and satisfaction |
54-56 |
88 (29/29/30) - (SC/PRS/TAP) |
Intervention: TAP – transversus abdominis plane catheter, PRS – posterior rectus sheath catheter, SC – subcutaneous catheter |
Mid line Laparotomy surgery |
No |
|
18 mL 0.5% ropivacaine via catheter |
Dexamethasone, Metoclopramide, Paracetamol, NSAIDs |
Kartalov et al., 2017 |
North Macedonia |
RCT |
Primary: VAS pain scores, total morphine dose over 24 hours |
Mean (SD): Intervention –41.3(15.8) Control –42.4(14.7) |
60 (30/30) |
Intervention: general anesthesia with RSB Control: no block |
Umbilical hernia repair surgery |
Yes |
I-II |
20 mL 0.25% bupi-vacaine bilaterally |
Paracetamol, morphine IV |
Kauffman et al., 2020 |
USA |
RCT |
Primary: pain score 60 minutes after the PACU arrival Secondary: pain (PACU), length of PACU stay, outpatient pain scores, outpatient opioid use, adverse events. |
10-21 Total: 15.3(3.1), control: 15.8(1.6), intervention: 14.83(4.0) |
48 (24/24) |
Intervention: laparoscopic-guided RSB. Control: trans-incisional RSB |
Single-incision laparoscopic cholecystectomy surgery (gail-bladder removal) |
Yes |
I-II |
0.5 mL/kg 0.2% ropivacaine hydrochloride bilaterally (total 1 mL/kg, total maximum dose 10 mL) |
Ondansetron IV, dexamethasone, glycopyrrolate |
Li et al., 2019 |
China |
RCT |
Primary: incidence of positive hemodynamic response at incision, incidence of moderate pain postoperatively Secondary: intraoperative sufentanyl, time to eye opening, time to extubation, time to oxycodone request, duration of sensory block |
46-70 Mean (SD):Group B – 58.0 (8.3), Group C – 56.4 (8.6), Group D – 58.7 (7.1), Group BD – 57.1 (8.3) |
85 (66/19) 1 control group: 19 (Group C) 3 intervention groups: 22 (Group B), 21 (Group D) and 23 (Group BD) |
Intervention: ultrasound-guided RSB (Group B), dexmedetomidine infusion (Group D), both RSB and dexmedetomidine (Group BD) Control: nothing (Group C) |
Open gastrectomy surgery (stomach removal) |
Yes |
I-III |
Group B: 20 mL 0.375% ropivacaine diluted in 0.9% saline bilaterally only Group D: initial dose 0.6 μg/kg dexmedetomidine followed by continuous infusion 0.2 μg/kg/h during surgery then followed by 10 μg sufentanyl Group BD: combination of Group B analgesics first followed by Group D analgesics |
Dexmedetomidine, sufentanyl |
Murouchi et al., 2015 |
USA |
RCT |
Concentration changes of Ropivacaine and analgesic effects |
18-85 |
22 (11/11) |
Intervention: RSB Control: TAPB |
laparoscopic ovarian surgery |
Yes |
I-II |
30mL 0.5% ropivacaine bilaterally, 15mL per side |
droperidol, acetaminophen |
Xu et al., 2018 |
China |
RCT |
Primary: effectiveness and safety |
75-77 |
60 (30/30) -(R+D/R) |
Intervention: R+D (10mL0.25% ropivacaine + 0.5 μg/kg dexmedetomidine); R (10 mL 0.25% ropivacaine) |
Emergency abdominal surgery |
Patient-controlled intravenous analgesia (PCIA) |
II-III |
10 mL 0.25% ropivacaine, + 0.5 μg/kg dexmedetomidine bilaterally |
Sufentanil, Cardiovascular medications |
Yentis et al., 1999 |
UK |
RCT |
Pain scores, morphine requirements |
32-71 |
37(21/16) |
Intervention: midline incisions Control: transverse incisions |
abdominal gynecological surgery |
Yes |
I-II |
Up to 60 ml bupivacaine 0.25% |
adrenaline 1:400 000 |